vTv Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). In the filing, the company gave an expected price range of $15 to $17 for about 7.81 million shares, with an overallotment option for an additional 1.17 million shares. The total offering at the maximum price would be valued at $152.73 million. The company plans to list on the Nasdaq Global Market under the symbol VTVT.

The underwriters for the offering are Piper Jaffray, Stifel, Canaccord Genuity and Janney Montgomery Scott.

This is a clinical-stage biopharmaceutical company is engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a strong pipeline of clinical drug candidates, led by its programs for the treatment of Alzheimer’s disease and type 2 diabetes.

The drug candidate for the treatment of Alzheimer’s, azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, and the company has commenced patient enrollment in a Phase 3 clinical trial under an FDA-agreed Special Protocol Assessment. The type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator, for which vTv is currently enrolling patients in a Phase 2b clinical trial. Another is TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which the company anticipates will enter a Phase 2 clinical trial in early 2016. vTv has three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

ALSO READ: 4 Large Cap Biotech Stocks to Buy Before Earnings

vTv Therapeutics will use the net proceeds of this offering to acquire vTv Therapeutics LLC units. The company intends to use the proceeds for the following purposes:

• Roughly $70.0 million to $80.0 million to fund the Phase 3 clinical development of azeliragon, including the Steadfast Study
• About $10.0 million to $15.0 million to fund the planned Phase 2 trials for the clinical development of our type 2 diabetes drug candidates
• The remainder to fund further clinical development of our other drug candidates and for working capital and other general corporate purposes

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.